Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00749515 · ClinicalTrials.gov registry record · Phase 4

Pilot Study for Patients With Poor Response to Deferasirox

A Phase 4 study, sponsored by Boston Children's Hospital.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target

NCT00749515 is a Phase 4 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00749515, a Phase 4 study, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target

Study Summary

This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload. The hypothesis is that patients with poor responses have physiologic barriers to deferasirox that may include absorption, pharmacokinetics of drug metabolism, hepatic clearance and/or genetic factors.

Interventions

  • DRUG Deferoxamine
  • DRUG Deferasirox
  • RADIATION HIDA

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2008-03
Est. Completion 2008-11
Phase Phase 4

Sponsor

Boston Children's Hospital

462 total trials

What the Registry Record Tells You About NCT00749515

The ClinicalTrials.gov registry entry for NCT00749515 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Deferoxamine is the first listed.

NCT00749515 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00749515 about?

NCT00749515 is a clinical study titled "Pilot Study for Patients With Poor Response to Deferasirox". This purpose of this study is to understand the differences between people who have a good response to deferasirox (exjade) compared to people who have a poor response to this medication when used for transfusion-dependent iron overload. The hypothesis is that patients with poor responses have phys...

What is the current status of trial NCT00749515?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2008-03. Estimated completion is 2008-11.

What interventions are being tested in trial NCT00749515?

The interventions under investigation include: Deferoxamine (DRUG), Deferasirox (DRUG), HIDA (RADIATION).

Who is sponsoring clinical trial NCT00749515?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.